<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52003">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01972230</url>
  </required_header>
  <id_info>
    <org_study_id>17713</org_study_id>
    <secondary_id>Claudia</secondary_id>
    <nct_id>NCT01972230</nct_id>
  </id_info>
  <brief_title>Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the possible protective effect of anesthetic technique balanced
      (BAL) compared to total intravenous anesthetic technique (TIVA-TCI) in ischemia reperfusion
      injury in microvascular flap in plastic surgery. The investigators will evaluate the
      viability of the flap using tissue oximetry monitoring and the level of biochemical markers
      in a circle at the end of the intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>tissutal oximetry average value of the flap measured with  INVOS (In Vivo Optical Spectroscopy) system continuously.</measure>
    <time_frame>24 hours from the end of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Microvascular Breast Flap in Plastic Surgery</condition>
  <arm_group>
    <arm_group_label>Bilanced group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.
Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Bilanced group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprivan + Remifentanil TCI</intervention_name>
    <arm_group_label>TCI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 yr

          -  ASA (American Society of Anesthesiology) I-II

        Exclusion Criteria:

          -  Known unusual reaction to anesthetic drugs

          -  Evaluation of anesthesia increased risk for malignant hyperthermia.

          -  History of vascular disease.

          -  History of bleeding diathesis.

          -  Tabagism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>federica falcioni</last_name>
    <phone>00390652665353</phone>
    <email>falciof@ifo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regina Elena Cancer Institute</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Forastiere Ester</last_name>
      <phone>00390652662994</phone>
      <email>forastiere@ifo.it</email>
    </contact>
    <investigator>
      <last_name>Claudia Claroni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>October 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ester Forastiere</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
